VALIDATION OF AN ECONOMIC TOOL TO ESTIMATE THE DIRECT COSTS FOR PATIENTS WITH CHRONIC KIDNEY DISEASE (CKD) ASSOCIATED WITH TYPE 2 DIABETES (T2D) IN COLOMBIA, ECUADOR, PERU, GUATEMALA, AND EL SALVADOR, AND TO ESTIMATE THE RETURN ON INVESTMENT (ROI...
Author(s)
Claudia A. López-Cabra, MD, MSc1, Ángela Daniela Rodríguez, BEc, MSc2, Diana Smith Lopez, BEc, MSc2, Diana Gutierrez, MD1, wilson Mayorga Mogollon, BEc, MSc2;
1Bayer, Bogota, Colombia, 2Numeris, Bogota, Colombia
1Bayer, Bogota, Colombia, 2Numeris, Bogota, Colombia
OBJECTIVES: 1)Validate the methodology estimation and overall direct costs for patients with CKD and T2D through microcosting in Colombia, Ecuador, Peru, Guatemala, and El Salvador. 2) Assess services for hospitalized CKD and T2D patients due to cardiovascular events and 3) Analyze the economic impact of finerenone, estimating avoided direct costs and ROI
METHODS: Expert consensus was used as a methodological strategy, integrating the expert judgment method and the Nominal Group Technique (NGT). Key stages included problem specification, evaluation point definition, structured discussions, and result validation, with consensus achieved when at least two experts agreed on an element. For Colombia, criteria were established to create a unique model of a typical patient reflecting clinical practice and the estimation methodology of the technical note (NT). The ROI was evaluated by estimating total cost savings from finerenone (decrease in dialysis and in hospitalizations due to cardiovascular events -CV) over its cost, projected annually and cumulatively over ten years using FIDELITY study
RESULTS: Study included two nephrologists and one cardiologist from Colombia, two nephrologists and one cardiologist from Central America, one nephrologist from Ecuador, and one nephrologist and one cardiologist from Peru. Experts validated the classification of patients by albuminuria stages and deemed the methodology suitable for assessing direct costs. They also agreed on the technical note and costing methodology in Colombia. A positive ROI was observed from the first year, reaching between 35% and 50%, and, over 10-year horizon, the ROI of finerenone is upward, and it is estimated that, in most countries, by the fifth year of treatment for the cohort of patients with CKD and T2D, savings will be generated compared to the investment in finerenone plus the standard of care
CONCLUSIONS: Experts validated the cost estimation tool for CKD and T2D, assessing renal and cardiovascular outcomes, and confirmed finerenone’s positive ROI and economic viability
METHODS: Expert consensus was used as a methodological strategy, integrating the expert judgment method and the Nominal Group Technique (NGT). Key stages included problem specification, evaluation point definition, structured discussions, and result validation, with consensus achieved when at least two experts agreed on an element. For Colombia, criteria were established to create a unique model of a typical patient reflecting clinical practice and the estimation methodology of the technical note (NT). The ROI was evaluated by estimating total cost savings from finerenone (decrease in dialysis and in hospitalizations due to cardiovascular events -CV) over its cost, projected annually and cumulatively over ten years using FIDELITY study
RESULTS: Study included two nephrologists and one cardiologist from Colombia, two nephrologists and one cardiologist from Central America, one nephrologist from Ecuador, and one nephrologist and one cardiologist from Peru. Experts validated the classification of patients by albuminuria stages and deemed the methodology suitable for assessing direct costs. They also agreed on the technical note and costing methodology in Colombia. A positive ROI was observed from the first year, reaching between 35% and 50%, and, over 10-year horizon, the ROI of finerenone is upward, and it is estimated that, in most countries, by the fifth year of treatment for the cohort of patients with CKD and T2D, savings will be generated compared to the investment in finerenone plus the standard of care
CONCLUSIONS: Experts validated the cost estimation tool for CKD and T2D, assessing renal and cardiovascular outcomes, and confirmed finerenone’s positive ROI and economic viability
Conference/Value in Health Info
2026-05, ISPOR 2026, Philadelphia, PA, USA
Value in Health, Volume 29, Issue S6
Code
EE86
Topic
Economic Evaluation
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies
Disease
SDC: Diabetes/Endocrine/Metabolic Disorders (including obesity), SDC: Urinary/Kidney Disorders